NeOnc Advances Brain Cancer Programs With Encouraging Phase 2 Progress

NeOnc Technologies reported first-quarter 2026 financial results while highlighting progress across its clinical-stage programs targeting central nervous system cancers. The company successfully completed the Phase 1 dose escalation study for NEO-212, establishing a recommended Phase 2 dose and advancing development toward key regulatory milestones.

Management also reported encouraging early signs of clinical activity and potential durable disease stabilization in patients with recurrent glioblastoma multiforme (GBM) and brain metastases, despite the trial primarily being designed to evaluate safety.

#NeOncTechnologies
#Biotech
#BrainCancer
#Glioblastoma
#GBM
#ClinicalTrials
#Oncology
#CancerResearch
#DrugDevelopment
#HealthcareInnovation
#MedicalResearch
#Pharmaceuticals
#CNS
#JaneKing
#NewsOut